Global Insulin Delivery Systems Market 2016-2020 with Novo Nordisk, Sanofi, BD, Eli Lilly & Medtronic Dominating

Dublin, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Insulin Delivery Systems Market 2016-2020" report to their offering.

The global insulin delivery systems market to grow at a CAGR of 5.11% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global insulin delivery systems market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of insulin delivery systems. The report also includes a discussion of the key vendors operating in this market.

The cost of syringes and insulin pens is low, which enables users to opt for them as first choice devices. High cost of insulin pumps and insulin jet injectors poses a challenge to the growth of the market. Insulin pumps and jet injectors also require special care and maintenance, which is an additional cost burden to patients.

One of the key trends for market growth will be the presence of strategic alliances leading to innovative insulin delivery systems. In November 2015, Debiotech, the ARTORG Center for Biomedical Engineering Research of the University of Bern, and the Division of Endocrinology, Diabetes and Clinical Nutrition of the Bern University Hospital collaborated to develop a novel generation artificial pancreas for the personalized delivery of insulin with the accuracy of an MEMS based pump. The ambition is to create a substantial change in the treatment of diabetes and in the market for the artificial pancreas.

According to the report, one of the key drivers for market growth will be to focus on self-management of diabetes. The adoption of insulin delivery systems for type-1 diabetes management has increased in recent years. The adoption rate is increasing due to factors such as awareness, health consciousness, and a marginal improvement of healthcare policies allowing some reimbursement for insulin delivery devices.

The devices used in hospitals and specialty clinics are now being used in home care treatment by patients. This trend is seen largely because it helps save the visiting costs and fees of hospitals and clinics, and saves waiting time. In recent times, normal insulin injections are being used at home by patients with the guidance of a physician. Insulin pens, pumps, and jet injectors are handy and can be carried anywhere and can be used anytime. This flexibility has made insulin delivery device users opt for self-care diabetes management.

Key vendors

  • Novo Nordisk
  • Sanofi
  • BD
  • Eli Lilly
  • Medtronic

Other prominent vendors

  • Animas
  • Beta Bionics
  • Cellnovo
  • Copernicus
  • Dance Biopharm
  • Debiotech
  • InsuJet
  • Insulet
  • MannKind
  • Owen Mumford
  • Roche
  • SHL
  • Tandem Diabetes Care
  • Valeritas
  • West Pharma
  • Ypsomed

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Market segmentation by product

Part 07: Market segmentation by end-user

Part 08: Geographical segmentation

Part 09: Market drivers

Part 10: Impact of drivers

Part 11: Market challenges

Part 12: Impact of drivers and challenges

Part 13: Market trends

Part 14: Vendor landscape

Part 15: Key vendor analysis

Part 16: Appendix

For more information about this report visit

Related Topics: Diabetes Devices

CONTACT: Research and Markets
         Laura Wood, Senior Manager

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716